Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EPRX Eupraxia Pharmaceuticals

Trading 09-28 10:10:38 EDT

8.06

+0.05

+0.56%

High8.11	Low7.84	Vol55.46K
Open7.84	D1 Closing8.01	Amplitude3.36%
Mkt Cap532.22M	Tradable Cap438.97M	Total Shares66.07M
T/O442.97K	T/O Rate0.10%	Tradable Shares54.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":8.055,"timestamp":1790604625015,"preClose":8.01,"halted":0,"volume":55458,"delay":0,"changeRate":0.005617977528089879,"floatShares":54496455,"shares":66073400,"eps":-0.996725,"marketStatus":"Trading","change":0.045,"latestTime":"09-28 10:10:38 EDT","open":7.84,"high":8.1089,"low":7.84,"amount":442971.995076,"amplitude":0.033571,"askPrice":8.1,"askSize":110,"bidPrice":8.01,"bidSize":345,"shortable":3,"etf":0,"ttmEps":-0.996725,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790625600000},"marketStatusCode":2,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":8.01,"preHourTrading":{"tag":"盘前","latestPrice":8.49,"preClose":8.01,"latestTime":"04:52 EDT","volume":1,"amount":8.49,"timestamp":1790585557010,"change":0.48,"changeRate":0.059925,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":8.01,"preClose":8.01,"latestTime":"19:30 EDT","volume":284,"amount":2275.19,"timestamp":1790379006446,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.748336},"requestUrl":"/m/hq/s/EPRX/wiki","defaultTab":"wiki","newsList":[{"id":"2669498703","title":"Eupraxia Pharmaceuticals Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669498703?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:48","pubTimestamp":1790254080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467696","title":"Eupraxia Pharmaceuticals Inc : Wedbush Initiates Coverage with Outperform Rating; Price Target $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669467696?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:31","pubTimestamp":1790249486,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646290","title":"Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646290","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646290?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:04","pubTimestamp":1790247881,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) has an average rating of buy and mean price target of $15.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143356","title":"H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143356","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143356?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:45","pubTimestamp":1790070339,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $11...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378175","title":"Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378175","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378175?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Sept.  08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveragi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357580/0/en/eupraxia-pharmaceuticals-completes-transfer-to-the-nasdaq-global-select-market-and-announces-participation-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664480982","title":"Eupraxia Pharmaceuticals management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664480982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664480982?lang=en_us&edition=fundamental","pubTime":"2026-09-04 02:40","pubTimestamp":1788460812,"startTime":"0","endTime":"0","summary":"Meeting to be held on September 9 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659545611","title":"Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2659545611","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659545611?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622400,"startTime":"0","endTime":"0","summary":"The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post trea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344441/0/en/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-1b-2a-resolve-trial-including-new-data-on-odynophagia-painful-swallowing-in-eosinophilic-esophagitis-p.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194647","title":"Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194647","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194647?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:32","pubTimestamp":1786483947,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61130473/eupraxia-pharmaceuticals-q2-eps-0-23-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658946271","title":"Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658946271","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658946271?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:21","pubTimestamp":1786483260,"startTime":"0","endTime":"0","summary":"New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3343238/0/en/eupraxia-pharmaceuticals-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657821016","title":"Eupraxia Pharmaceuticals files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2657821016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657821016?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:17","pubTimestamp":1786011434,"startTime":"0","endTime":"0","summary":"06:12 EDT Eupraxia Pharmaceuticals (EPRX) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656745843","title":"David Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2656745843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656745843?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:16","pubTimestamp":1785762964,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Martin PhD from Bloom Burton m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/david-martin-reiterates-buy-on-eupraxia-pharmaceuticals-citing-strong-kol-support-for-ep-104gis-commercialization-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/david-martin-reiterates-buy-on-eupraxia-pharmaceuticals-citing-strong-kol-support-for-ep-104gis-commercialization-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","KOL","XBI","XLV","EP","BK4588","BK4581","BK4213","EPRX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356027","title":"Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356027?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:35","pubTimestamp":1785486936,"startTime":"0","endTime":"0","summary":"William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on EPRX stock, giving a Buy rating on July 21. Lachlan Hanbury Brow...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-backed-by-ep-104gis-seamless-fit-into-gi-practice-and-strong-commercial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EP","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009495","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009495","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009495?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:29","pubTimestamp":1785238169,"startTime":"0","endTime":"0","summary":"FiEE  shares were down 20% in Tuesday premarket trading, following the earlier session's nearly 13% gain.Eupraxia Pharmaceuticals  stock was down 15% after a 6.2% gain in Monday's session.Nomadar  shares were down 14%, following the previous session's 16% gain.Brenmiller Energy  stock was down 13%, extending the previous session's nearly 17% decline.China SXT Pharmaceuticals  shares were down 10% after the earlier session's 9.4% gain.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4133","EPRX","BNRG","SXTC","BK4139","NOMA","BK4182","BK4108","FIEE","BK4020","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653789837","title":"Buy Rating Reaffirmed on EPRX as EP-104GI Catalyst Nears and $16 Price Target Remains Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2653789837","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653789837?lang=en_us&edition=fundamental","pubTime":"2026-07-22 06:02","pubTimestamp":1784671367,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital mai...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-on-eprx-as-ep-104gi-catalyst-nears-and-16-price-target-remains-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-on-eprx-as-ep-104gi-catalyst-nears-and-16-price-target-remains-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","EP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652216138","title":"Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652216138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652216138?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:15","pubTimestamp":1784553358,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $19.00. According to T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651447144","title":"Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2651447144","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651447144?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:58","pubTimestamp":1783976336,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. Eupraxia Pharmaceuticals has reshaped its executive leadership and operat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-overhauls-leadership-and-operations-ahead-of-key-eoe-trial-milestone?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-overhauls-leadership-and-operations-ahead-of-key-eoe-trial-milestone?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651414126","title":"Eupraxia chief scientific and operating officer Amanda Malone steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2651414126","media":"TIPRANKS","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651414126?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:15","pubTimestamp":1783973725,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) announced Amanda Malone has stepped down from her role as chief scientific and operating officer, effective July 10...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-chief-scientific-and-operating-officer-amanda-malone-steps-down-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-chief-scientific-and-operating-officer-amanda-malone-steps-down-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651419461","title":"Eupraxia Names Jeff Millard EVP Technical Operations as Amanda Malone Steps Down COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651419461","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651419461?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:06","pubTimestamp":1783973160,"startTime":"0","endTime":"0","summary":"Eupraxia names Jeff Millard EVP technical operations as Amanda Malone steps down COOEupraxia named Jeff Millard executive vice president, technical operations, effective July 13, 2026.Millard brings n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL1lCwx2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651514415","title":"Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2651514415","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651514415?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:05","pubTimestamp":1783973100,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, July  13, 2026  (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveragi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326453/0/en/Eupraxia-Pharmaceuticals-Strengthens-Executive-Leadership-Team-to-Support-Next-Phase-of-Growth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX","TISI","BK4120"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987399","title":"Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987399?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:00","pubTimestamp":1783425600,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, July  07, 2026  (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323104/0/en/Eupraxia-Pharmaceuticals-Strengthens-Board-with-Three-Industry-Leaders-in-Drug-Development-and-Commercialization.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GVP","EPRX","BK4023","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eupraxiapharma.com","stockEarnings":[{"period":"1week","weight":-0.0664},{"period":"1month","weight":0.0781},{"period":"3month","weight":0.2136},{"period":"6month","weight":0.192},{"period":"1year","weight":0.3906},{"period":"ytd","weight":0.0609}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.","exchange":"NASDAQ","name":"Eupraxia Pharmaceuticals","nameEN":"Eupraxia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eupraxia Pharmaceuticals,EPRX,Eupraxia Pharmaceuticals股票,Eupraxia Pharmaceuticals股票老虎,Eupraxia Pharmaceuticals股票老虎国际,Eupraxia Pharmaceuticals行情,Eupraxia Pharmaceuticals股票行情,Eupraxia Pharmaceuticals股价,Eupraxia Pharmaceuticals股市,Eupraxia Pharmaceuticals股票价格,Eupraxia Pharmaceuticals股票交易,Eupraxia Pharmaceuticals股票购买,Eupraxia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}